Medicines & Treatments
FOXO4-DRI 10 mg
FOX04-DRI 10 mg – Peptide Hubs FOX04-DRI is a cutting-edge synthetic peptide designed to selectively induce apoptosis in senescent cells while preserving healthy tissue. By interfering with the FOXO4-p53 interaction, this peptide holds immense potential in research related to cellular aging, tissue regeneration, and age-related pathologies. Peptide Hubs offers a 10 mg lyophilized vial of FOX04-DRI, designed for stable and precise use in experimental setups. What Is FOX04-DRI? FOX04-DRI (FOXO4 D-Retro-Inverso) is a modified peptide sequence that mimics a portion of the natural FOXO4 protein but with reverse amino acid direction and D-amino acids for enhanced stability. It works by disrupting the binding of FOXO4 to p53, allowing senescent cells to undergo apoptosis without harming healthy cells. Its primary relevance lies in the field of senolytics—therapies aimed at removing aging or "zombie" cells. For more on the underlying science, read this NIH study on FOXO4-DRI and senescence clearance.
Fermawin 2.5 mg
Dragon Pharma FermaWin 2.5 mg – Stanozolol for Cutting and Performance Research ✔ Active substance: Stanozolol ✔ Non-aromatizing DHT derivative ✔ Studied for strength & lean tissue preservation ✔ USA domestic shipping available Dragon Pharma FermaWin 2.5 mg is an oral formulation containing Stanozolol, a synthetic derivative of dihydrotestosterone (DHT). This compound has been extensively researched for its ability to promote strength gains, enhance vascularity, and preserve lean muscle tissue during caloric deficits, making it a popular subject of study in cutting and performance research. Each package contains 100 tablets at 2.5 mg per tablet, supplied in a manufacturer sachet. Stanozolol is known for its non-aromatizing properties and its ability to increase protein synthesis and red blood cell production. For related research compounds, explore our orals category and specifically Anavar 10 for complementary research applications. What Makes FermaWin Valuable in Research? Stanozolol is a DHT-derived compound that binds to androgen receptors with high affinity while exhibiting minimal estrogenic activity. Its unique properties include increased protein synthesis, enhanced nitrogen retention, and reduced levels of sex hormone-binding globulin (SHBG), which can increase free testosterone levels. These characteristics make it a valuable research tool for investigating anabolic mechanisms without water retention. Researchers value FermaWin for its well-characterized profile and its applications in studies examining muscle preservation, strength enhancement, and performance optimization. For investigators exploring other DHT-derived compounds, Proviron offers complementary research avenues in androgen receptor modulation. Current scientific literature on Stanozolol can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications. Key Research Applications for Dragon Pharma FermaWin ✔ Investigation of DHT-derived anabolic compounds ✔ Evaluation of lean tissue preservation during caloric restriction ✔ Research on strength enhancement and performance ✔ Studies of non-aromatizing androgenic compounds ✔ Preclinical models of muscle preservation and conditioning For Research Purposes Only FermaWin 2.5 mg is intended for research use only and is not approved for human consumption. Proper handling, dosing, and experimental protocols are essential for reliable results. For studies on performance enhancement, Winstrol 10 provides additional research avenues with different dosing parameters.
